Corcept Therapeutics Inc insider trading
Every open-market purchase and sale by Corcept Therapeutics Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Corcept Therapeutics Inc’s insiders pay?
From April 23, 2010 to August 28, 2026, 21 insiders reported 32 open-market purchases and 84 sales not made under a pre-set plan in Corcept Therapeutics Inc. Twelve months after each purchase was reported, the shares were −10.7% against the S&P 500 on average (median −10.8%), over 16 purchases with a full year of prices; 19% beat the index. After sales, the shares moved +11.0% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 9, 2017 into $27,968 by November 2, 2026, +11.5% a year. It held shares 47% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $18,323 (+6.6% a year), and held throughout $36,619 (+14.7%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Baker G Leonard Jr | Director | 20 | −14.0% (14) | 14% | 5 | −15.4% (5) | March 19, 2026 |
| Robb Gary Charles | Chief Business Officer | 1 | +51.4% (1) | 100% | 17 | +11.6% (16) | August 18, 2026 |
| Enright Patrick G | Director | 1 | — | — | 11 | +52.0% (8) | March 20, 2017 |
| Wilson James N | Director | 0 | — | — | 11 | +6.6% (8) | November 14, 2016 |
| Bradbury Daniel | Director | 2 | — | — | 6 | +12.8% (4) | December 11, 2015 |
| Mahoney David L | Director | 2 | — | — | 5 | −0.3% (4) | June 18, 2026 |
| Roe Robert L | President and Secretary | 0 | — | — | 7 | — | August 6, 2012 |
| Cook Joseph C Jr | Director | 3 | — | — | 1 | −25.3% (1) | March 25, 2015 |
| Lo Steven | VP Commercial Operations | 0 | — | — | 4 | — | November 3, 2015 |
| Lyon Joseph Douglas | See Remarks | 0 | — | — | 4 | +14.4% (2) | August 5, 2026 |
| Belanoff Joseph K | Chief Executive Officer | 0 | — | — | 3 | +36.3% (3) | December 14, 2018 |
| Longitude Capital Associates, L.P. | Director | 1 | — | — | 1 | — | May 5, 2014 |
| Longitude Capital Partners, LLC | Director | 0 | — | — | 2 | −22.8% (1) | March 24, 2015 |
| Maduck Sean | See Remarks | 0 | — | — | 2 | −42.9% (2) | February 16, 2021 |
| Gala Renee D | Director | 1 | −27.8% (1) | 0% | 0 | — | March 7, 2018 |
| Guyer William | Chief Development Officer | 0 | — | — | 1 | — | November 26, 2025 |
| Hunt Hazel | Chief Scientific Officer | 0 | — | — | 1 | −16.7% (1) | August 15, 2023 |
| Longitude Venture Partners L.P. | Director | 0 | — | — | 1 | — | April 3, 2014 |
| Park Kimberly | Director | 0 | — | — | 1 | — | August 28, 2026 |
| Swisher Daniel N Jr | Director | 0 | — | — | 1 | +3.4% (1) | August 9, 2022 |
| Turner Joseph L | Director | 1 | — | — | 0 | — | March 14, 2013 |
When several insiders traded Corcept Therapeutics Inc
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Corcept Therapeutics Inc in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 4 selling crowds, −15.0%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| August 31, 2026 | 4 selling | not yet | not yet | not yet |
| December 31, 2018 | 3 selling | −29.5% | −39.5% | −40.7% |
| November 30, 2016 | 6 selling | +7.3% | +31.3% | +91.1% |
| July 31, 2015 | 3 selling | −24.5% | −22.4% | +9.2% |
| March 31, 2015 | 6 selling | +7.1% | −29.4% | −18.1% |